Viking Therapeutics Inc (VKTX) Short Interest Up 48.1% in January

Viking Therapeutics Inc (NASDAQ:VKTX) was the recipient of a large growth in short interest in the month of January. As of January 12th, there was short interest totalling 1,965,269 shares, a growth of 48.1% from the December 29th total of 1,326,621 shares. Based on an average trading volume of 833,219 shares, the short-interest ratio is currently 2.4 days. Approximately 8.1% of the shares of the stock are short sold.

Shares of Viking Therapeutics (NASDAQ:VKTX) opened at $5.63 on Friday. Viking Therapeutics has a twelve month low of $0.88 and a twelve month high of $5.95. The stock has a market capitalization of $180.16, a PE ratio of -6.70 and a beta of 1.88.

Viking Therapeutics (NASDAQ:VKTX) last posted its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.03). research analysts expect that Viking Therapeutics will post -0.86 EPS for the current year.

A number of equities research analysts have recently commented on the company. Roth Capital set a $6.00 target price on Viking Therapeutics and gave the company a “buy” rating in a research report on Wednesday, November 29th. ValuEngine cut Viking Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Maxim Group restated a “buy” rating and set a $5.00 target price on shares of Viking Therapeutics in a research report on Wednesday, October 4th. Finally, HC Wainwright restated a “buy” rating and set a $7.00 target price on shares of Viking Therapeutics in a research report on Friday, November 10th.

A number of hedge funds have recently bought and sold shares of VKTX. Citadel Advisors LLC acquired a new stake in Viking Therapeutics in the 3rd quarter worth about $108,000. Virtu KCG Holdings LLC acquired a new stake in Viking Therapeutics in the 2nd quarter worth about $124,000. Creative Planning boosted its holdings in Viking Therapeutics by 600.0% in the 4th quarter. Creative Planning now owns 70,000 shares of the biotechnology company’s stock worth $284,000 after buying an additional 60,000 shares during the last quarter. Sabby Management LLC acquired a new stake in Viking Therapeutics in the 2nd quarter worth about $525,000. Finally, Sphera Funds Management LTD. acquired a new stake in Viking Therapeutics in the 3rd quarter worth about $554,000. Institutional investors own 5.65% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Viking Therapeutics Inc (VKTX) Short Interest Up 48.1% in January” was first posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2018/01/28/viking-therapeutics-inc-vktx-short-interest-up-48-1-in-january.html.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply